Aptorum Gr (NASDAQ:APM) reported quarterly losses of $(0.62) per share. This is a 77.45 percent increase over losses of $(2.75) per share from the same period last year. The company reported $431.38 thousand in sales this quarter. This is a 66.71 percent decrease over sales of $1.30 million the same period last year.
Save time and jump to the most important pieces.
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing
ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_accessASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years
ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO and Executive Chairman Darren Lui discusses the Company's pipeline for oncology, autoimmune, and infectious diseases, a $15 billion market opportunity, the comp
SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)
SC 13G/A - Aptorum Group Ltd (0001734005) (Subject)
SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)
6-K - Aptorum Group Ltd (0001734005) (Filer)
6-K - Aptorum Group Ltd (0001734005) (Filer)
6-K/A - Aptorum Group Ltd (0001734005) (Filer)
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12023334
Re: Amendment to Merger Agreement Dear Wong Ling Yan Philip:Reference is made to that certain Agreement dated March 1, 2024, (the "Merger Agreement") by and between YOOV Group Holding Limited (the "Company") and Aptorum Group Limited (the "ListCo"), relating to a plan of merger and separation. References to capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Merger Agreement.
Gainers Innovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) shares increased by 66.66% to $2.45. The market value of their outstanding shares is at $58.4 million. TransCode Therapeutics (NASDAQ:RNAZ) stock rose 28.05% to $1.78. The company's market cap stands at $11.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 20.15% to $0.17. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 4 days ago. Aptorum Gr (NASDAQ:APM) shares moved upwards by 17.2% to $4.7. The market value of their outstanding
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented, "Throughout 2023, we have maintained a strategic focus on the progression of our lead projects to effectively utilize our resources. Additionally, the previously announced proposed reverse merger with YOOV Group Holding demonstrates our commitment to shareholder interests a
Aptorum Group Limited (NASDAQ:APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum's and YOOV's boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Aptorum's and YOOV's shareholders (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing", and the da
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all seven directors to hold office until the next annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP (formerly know
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced the results of its 2021 annual general meeting of shareholders, which was held on December 2, 2021, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: Re-elected all of the Company's current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner as directors of the Company until the Company's next annual general meeting o